has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Marksans Pharma
to report net profit at Rs 12.7 crore, up 1133 percent quarter-on-quarter.
Net Sales are expected to increase by 12.4 percent Q-o-Q (down 17.8 percent Y-o-Y) to Rs 210 crore, according to Centrum.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 195.9 percent Q-o-Q (down 52.3 percent Y-o-Y) to Rs 24.5 crore.
Centrum's report on Marksans Pharma
We expect Marksans Pharma’s (MPL) revenue to decline by 18% YoY and grow by 12% QoQ to Rs2.10bn due to restrictive imports of company’s products in UK. MPL’s UK business (38% of revenues) is likely to decline by 28% YoY to Rs 790mn as the company has been permitted to export only critical products to the UK market.
The company’s US business (44% of revenues) is expected to decline by 19% YoY and grow by 17% QoQ due to integration of TCL during the year and commencement ofsupplies to Walgreen from Q1FY17. The company is set to report 64% YoY decline in net profit to Rs 127mn from Rs 349mn.Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.